- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03894670
Evaluation of Methods for Measuring Gastrointestinal Transit and Food Reward in Healthy Individuals - The PRESET Study (PRESET)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: The wireless motility capsule technology, SmartPill™, can be used to assess GI transit time including gastric emptying and small and large bowel transit time based on measurements of pH, pressure and temperature. The SmartPill™ allows for GI motility measurements under free-living conditions without radiation. The SmartPill is usually ingested together with a SmartBar™ which is a snack bar with a nutrient composition that differs substantially from a normal western diet. GI motility in response to meals plays an important role in regulation of e.g. appetite and glucose metabolism. Changes in appetite and metabolism in response to interventions are often assessed using a meal test and GI motility is assessed at the research facilities. The use of SmartPill™ in combination with a meal test would allow for assessment of GI motility under subsequent free-living conditions and improve our understanding of the effects of interventions on the integrative relationship between food intake, GI motility and metabolism. Most of our daily decisions and actions affecting energy intake are driven by the non-conscious processes; however, appetite is often assessed from participants' self-report which is associated with limitations such as desire to report socially desirable answers. Little is known about the complex interrelationship between biological markers of appetite e.g. GI hormones and subjective and objective measures of food related behavior under fasting and fed conditions.
The PRESET study has the following objectives:
- To compare effects of a SmartBar™ and a standard mixed breakfast meal on gastric emptying and GI transit time measured using the SmartPill™ in normal-weight individuals.
- To compare effects of a SmartBar™ and a standard mixed breakfast meal on concentrations of metabolites and pancreatic and GI hormones, and subjective and objective measures of appetite, food reward and food related behavior assessed from biometric responses (facial expression, galvanic skin response and eye tracking) to visual food stimuli varying in fat content and taste during the computerized Leeds Food Preference Questionnaire (LFPQ) in normal-weight individuals.
- To assess potential associations between gastric emptying and GI motility, biological markers of appetite and subjective appetite and objective measures of food related behavior from biometric responses to visual food stimuli during the LFPQ in the fasting state and in response to meals in normal-weight individuals.
Testing includes assessments in the fasting state and in response to consumption of the SmartBar™ and a standard mixed meal (4-hour meal tests and subsequent 6-days free-living assessment period) on two separate test days.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Gentofte, Denmark, DK-2810
- Steno Diabetes Center Copenhagen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
• Body mass index: 18.5 to 24.9 kg/m2
Exclusion Criteria:
- Unable to understand the informed consent and the study procedures;
- Self-reported history of an eating disorder in the past three years
- Self-reported weight change (>5 kg) within three months prior to inclusion
- HbA1c: ≥5.7 % (≥39 mmol/mol)
- Uncontrolled medical issues including but not limited to cardiovascular pulmonary, rheumatologic, hematologic, oncologic, infectious, GI or psychiatric disease; diabetes or other endocrine disease; immunosuppression
- Current treatment with medication or medical devices which affect GI motility and transit time (prokinetics, antidiarrheals, laxatives)
- Current treatment with medication which affect glucose metabolism or appetite
- Current treatment with beta blockers or peroral steroids
- Current treatment with non-steroidal anti-inflammatory drugs, tricyclic antidepressants, selective serotonin re-uptake inhibitors or opioids
- Bariatric surgery
- GI symptoms or diseases such as regular (weekly) abdominal pain, dysphagia, gastric bezoars, strictures, fistulas, bowel obstructions, diverticulitis, celiac disease, Crohn's disease, ulcerative colitis or proctitis
- Alcohol/drug abuse or in treatment with disulfiram (Antabus) at time of inclusion
- Pregnant or lactating women
- Fertile women not using birth control agents including oral contraceptives, gestagen injection, subdermal implants, hormonal vaginal ring, transdermal application, or intra-uterine devices
- Concomitant participation in other research studies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: SmartBar™
The wireless capsule technology, SmartPill™, is usually ingested together with a SmartBar™ which is a snack bar with a nutrient composition that differs substantially from a normal western diet.
|
SmarBar™ (Medtronic, North Haven, MA, USA).
Weight: 72 g; Total energy content: 260 kcal Macronutrient composition: 7 E% fat, 19 E% protein, 74 E% carbohydrate.
|
EXPERIMENTAL: Standard mixed breakfast meal
The SmartPill™ is ingested together with a standard mixed breakfast meal and the outcomes of interest will be compared with the SmartBar™ condition (reference).
|
The standard mixed breakfast meal consists of: 150 g yoghurt, 20 g muesli; 50 g wheat bun; 22 g rye bread; 25 g cheese; 25 g marmalade; 8 g butter; Total energy content: 500 kcal Macronutrient composition: 34 E% fat, 17 E% protein, 49 E% carbohydrate |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gastric emptying time (minutes)
Time Frame: Within 24 hours from ingestion of the SmartPill™ at both visits (standard breakfast meal and SmartBar™, respectively)
|
Measured by the SmartPill™ technique.
The SmartPill™ is ingested at both visits in combination with the standard breakfast meal and SmartBar™, respectively.
The time frame depends on the individual gastric emptying time.
|
Within 24 hours from ingestion of the SmartPill™ at both visits (standard breakfast meal and SmartBar™, respectively)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Small bowel transit time (minutes)
Time Frame: Within 5 days after both visits (standard breakfast meal and SmartBar™, respectively)
|
Measured by the SmartPill™ technique.
The SmartPill™ is ingested at both visits in combination with the standard breakfast meal and SmartBar™, respectively.
The time frame depends on the individual transit time.
|
Within 5 days after both visits (standard breakfast meal and SmartBar™, respectively)
|
Large bowel transit time (minutes)
Time Frame: Within 5 days after both visits (standard breakfast meal and SmartBar™, respectively)
|
Measured by the SmartPill™ technique.
The SmartPill™ is ingested at both visits in combination with the standard breakfast meal and SmartBar™, respectively.
The time frame depends on the individual transit time.
|
Within 5 days after both visits (standard breakfast meal and SmartBar™, respectively)
|
Total gastrointestinal transit time (minutes)
Time Frame: Within 5 days after both visits (standard breakfast meal and SmartBar™, respectively)
|
Measured by the SmartPill™ technique.
The SmartPill™ is ingested at both visits in combination with the standard breakfast meal and SmartBar™, respectively.
The time frame depends on the individual transit time.
|
Within 5 days after both visits (standard breakfast meal and SmartBar™, respectively)
|
Motility index (arbitrary unit)
Time Frame: Within 5 days after both visits (standard breakfast meal and SmartBar™, respectively)
|
Calculated based on amplitudes and number of contractions measured using the SmartPill™ technique.
The greater the motility index the greater the gastrointestinal motility (i.e. more frequent and stronger contractions).
A higher motility index has been observed among healthy participants compared to patients with diabetic gastroparesis indicating that a higher index is favorable.
|
Within 5 days after both visits (standard breakfast meal and SmartBar™, respectively)
|
Metabolites
Time Frame: 0 minutes (fasting) and 15, 30, 45, 60, 90, 120, 180, 240 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Concentrations of metabolites (including but not limited to: glucose, lipids, cholesterol, free-fatty acids, and amino acids.
Measured at both visits in the fasting state and for 4 hours after consumption of the standard breakfast meal and the SmartBar™, respectively.
|
0 minutes (fasting) and 15, 30, 45, 60, 90, 120, 180, 240 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Hormones
Time Frame: 0 minutes (fasting) and 15, 30, 45, 60, 90, 120, 180, 240 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Concentrations of hormones related to regulation of appetite, glucose and lipid metabolism (including but not limited to: insulin, glucagon, ghrelin, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and peptide YY (PYY), leptin, fibroblast growth factor 19 (FGF-19), fibroblast growth factor 21 (FGF-21), growth differentiation factor 15 (GDF-15)).
|
0 minutes (fasting) and 15, 30, 45, 60, 90, 120, 180, 240 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Attention measured using eye tracking
Time Frame: 0 minutes (fasting) at 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Eye tracking metrics including gaze duration bias, gaze direction bias, fixations, saccades, pupil size/dilation, distance to screen, ocular vergence and blinks to measure attention in response to looking at food pictures during the computerized Leeds Food Preference Questionnaire
|
0 minutes (fasting) at 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Arousal measured using galvanic skin response
Time Frame: 0 minutes (fasting) and after 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Changes in conductivity of skin (galvanic skin response) in response to looking at food pictures during the computerized Leeds Food Preference Questionnaire
|
0 minutes (fasting) and after 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Emotions measured using facial expression analysis
Time Frame: 0 minutes (fasting) and after 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Facial expression analyses using computer-vision algorithms (AFFDEX) to measure emotions in response to looking at food pictures during the computerized Leeds Food Preference Questionnaire
|
0 minutes (fasting) and after 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Food choice
Time Frame: 0 minutes (fasting) and after 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Food choice of food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire.
Food choice is determined based on frequency of selection made within each food category.
The scores range from 0-48 i.e. 0 = foods within a specific food category have not been selected at all to 48 = foods within a specific food category have been selected 48 times.
|
0 minutes (fasting) and after 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Implicit wanting
Time Frame: 0 minutes (fasting) and after 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Implicit wanting of food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire.
Implicit wanting is assessed based on food choice and response time for selected and non-selected food items as well as mean response time.
|
0 minutes (fasting) and after 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Explicit liking
Time Frame: 0 minutes (fasting) and after 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Explicit liking of 16 food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire.
Explicit liking is rated using visual analogue scales and the range is 0-100.
Each end represents the extremes e.g.
Question: "how pleasant would it be to taste this food right now?" Answer: "not at all" (rated 0 on the 0-100 scale) to "extremely" (rated 100 on the 0-100 scale).
|
0 minutes (fasting) and after 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Explicit wanting
Time Frame: 0 minutes (fasting) and after 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Explicit wanting of 16 food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire.
Explicit wanting is rated using visual analogue scales and the range is 0-100.
Each end represents the extremes e.g.
Question: "how much do you want some of this food now?" Answer: "not at all" (rated 0 on the 0-100 scale) to "extremely" (rated 100 on the 0-100 scale).
|
0 minutes (fasting) and after 60 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Subjective appetite
Time Frame: 0 minutes (fasting) and 15, 30, 45, 60, 90, 120, 180, 240 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Rated using visual analogue scales and includes sensations of: Hunger, fullness, satiety, prospective food consumption, wellbeing, nausea, thirst, desire to eat meat, salty, and sweet.
The scale range is 0-100 and each end represent the extremes e.g.
hunger rating: "I am not hungry at all" to "I have never been this hungry before".
|
0 minutes (fasting) and 15, 30, 45, 60, 90, 120, 180, 240 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)
|
Self-reported gastrointestinal symptoms (part 1)
Time Frame: Answered during test days (0-240 minutes)
|
Assessed from the questionnaire the Gastrointestinal Symptom Rating Scale (GSRS).
Rated on 7-point likert scales.
Range: 1 = absence of symptoms to 7 = very severe symptoms.
|
Answered during test days (0-240 minutes)
|
Self-reported gastrointestinal symptoms (part 2)
Time Frame: Answered during test days (0-240 minutes)
|
Assessed from the Gastrointestinal Symptom Score (PAGI-SYM).
Rated on 6-point likert scales.
Range: 1 = absence of symptoms to 6 = very severe symptoms.
|
Answered during test days (0-240 minutes)
|
Self-reported gastrointestinal symptoms (part 3)
Time Frame: Registered 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Number of symptoms.
Assessed from logs.
|
Registered 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Self-reported autonomic symptoms
Time Frame: Answered during test days (0-240 minutes)
|
Assessed from the questionnaire COMPASS31
|
Answered during test days (0-240 minutes)
|
Body weight (kg)
Time Frame: At 0 minutes (fasting) at both visits
|
Body weight is measured on a digital scale
|
At 0 minutes (fasting) at both visits
|
Body mass index (kg/m^2)
Time Frame: At 0 minutes (fasting) at both visits
|
Calculated from body weight (kg) and height (m)
|
At 0 minutes (fasting) at both visits
|
Fat mass (kg)
Time Frame: At 0 minutes (fasting) at both visits
|
Measured by Dual-energy X-ray Absorptiometry
|
At 0 minutes (fasting) at both visits
|
Fat percentage (%)
Time Frame: At 0 minutes (fasting) at both visits
|
Measured by Dual-energy X-ray Absorptiometry
|
At 0 minutes (fasting) at both visits
|
Fat free mass (kg)
Time Frame: At 0 minutes (fasting) at both visits
|
Measured by Dual-energy X-ray Absorptiometry
|
At 0 minutes (fasting) at both visits
|
Waist circumference (cm)
Time Frame: At 0 minutes (fasting) at both visits
|
Measured using tape measure
|
At 0 minutes (fasting) at both visits
|
Hip circumference (cm)
Time Frame: At 0 minutes (fasting) at both visits
|
Measured using tape measure
|
At 0 minutes (fasting) at both visits
|
Mean amplitude of glycaemic excursions (MAGE)
Time Frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Measured using continous glucose monitoring
|
Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Continuous overall net glycaemic action (CONGA)
Time Frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Measured using continous glucose monitoring
|
Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Daily time spent above different glucose concentrations (e.g. >6.1 mmol/L, >7.0 mmol/L, >7.8 mmol/L, and >11.1 mmol/L)
Time Frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Measured using continous glucose monitoring
|
Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Mean glucose concentrations
Time Frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Measured using continous glucose monitoring
|
Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Standard deviation of glucose concentrations
Time Frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Measured using continous glucose monitoring
|
Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Variation coefficients of glucose concentrations
Time Frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Measured using continous glucose monitoring
|
Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Resting energy expenditure (kcal/day)
Time Frame: At 0 minutes (fasting) at both visits
|
Measured by indirect calorimetry under resting and fasting conditions
|
At 0 minutes (fasting) at both visits
|
Substrate oxidation (respiratory exchange ratio)
Time Frame: At 0 minutes (fasting) at both visits
|
Measured by indirect calorimetry under resting and fasting conditions
|
At 0 minutes (fasting) at both visits
|
Systolic blood pressure (mmHg)
Time Frame: At 0 minutes (fasting) at both visits
|
Measured under resting and fasting conditions
|
At 0 minutes (fasting) at both visits
|
Diastolic blood pressure (mmHg)
Time Frame: At 0 minutes (fasting) at both visits
|
Measured under resting and fasting conditions
|
At 0 minutes (fasting) at both visits
|
Heart rate (bpm)
Time Frame: At 0 minutes (fasting) at both visits
|
Measured under resting and fasting conditions during measurements of blood pressure and in the supine position by a handheld ECG measuring device (Vagus™).
|
At 0 minutes (fasting) at both visits
|
Heart rate response to standing up from the supine position
Time Frame: At 0 minutes (fasting) at both visits
|
Measured by a handheld ECG measuring device (Vagus™).
|
At 0 minutes (fasting) at both visits
|
Heart rate response to inhalation and exhalation
Time Frame: At 0 minutes (fasting) at both visits
|
Measured by a handheld ECG measuring device (Vagus™).
|
At 0 minutes (fasting) at both visits
|
Heart rate response to forced exhalation during rest (valsalva maneuver)
Time Frame: At 0 minutes (fasting) at both visits
|
Measured by a handheld ECG measuring device (Vagus™).
|
At 0 minutes (fasting) at both visits
|
Microbiome content and diversity
Time Frame: One sample during 6 days after both visits
|
Determined from stool samples.
Bacterial DNA and RNA will be purified from the stool samples and changes in the microbiome composition and function will be estimated based on sequencing of the microbiomes' DNA and RNA.
Includes but is not limited to the Firmicutes/Bacteroidetes ratio.
|
One sample during 6 days after both visits
|
Physical activity (time spent at different intensities)
Time Frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Sedentary time, light, moderate and vigorous intensity physical activity.
Assessed from 24 h/day accelerometry
|
Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Physical activity (counts/min)
Time Frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Assessed from 24 h/day accelerometry
|
Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Physical activity energy expenditure (kcal/day)
Time Frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Assessed from 24 h/day accelerometry
|
Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Physical activity (MET hours)
Time Frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Assessed from 24 h/day accelerometry
|
Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Timing of physical activity (hh:mm)
Time Frame: Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Assessed from activity logs and 24 h/day accelerometry
|
Measured for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Energy intake (kcal/day)
Time Frame: Assessed for 3 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Assessed from diet records
|
Assessed for 3 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Macronutrient intake (energy percentage)
Time Frame: Assessed for 3 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Assessed from diet records
|
Assessed for 3 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Timing of dietary intake (hh:mm)
Time Frame: Assessed for 3 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Assessed from diet records
|
Assessed for 3 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Sleep timing (hh:mm)
Time Frame: Assessed for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Including bedtime, sleep onset, wake-up, time out of bed, sleep midpoint.
Assessed from sleep logs and 24 h/day accelerometry
|
Assessed for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Sleep duration (minutes)
Time Frame: Assessed for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Assessed from sleep logs and 24 h/day accelerometry
|
Assessed for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Sleep variability (minutes)
Time Frame: Assessed for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Variability in bedtime, wake-up, sleep duration and sleep midpoint.
Assessed from sleep logs and 24 h/day accelerometry
|
Assessed for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Sleep onset latency (minutes)
Time Frame: Assessed for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Assessed from sleep logs and 24 h/day accelerometry
|
Assessed for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Sleep efficiency (%)
Time Frame: Assessed for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Assessed from 24 h/day accelerometry
|
Assessed for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Wakefulness (minutes)
Time Frame: Assessed for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
Assessed from 24 h/day accelerometry
|
Assessed for 6 days after both visits (standard breakfast meal and the SmartBar™ conditions)
|
HbA1c (mmol/mol and %)
Time Frame: At 0 minutes at both visits
|
Hemoglobin A1c
|
At 0 minutes at both visits
|
Insulin sensitivity (indices)
Time Frame: At 0 minutes (fasting) and 4 hours after consumption of the standard breakfast meal and the SmartBar™, respectively
|
Including but not limited to the Matsuda index
|
At 0 minutes (fasting) and 4 hours after consumption of the standard breakfast meal and the SmartBar™, respectively
|
Insulin resistance (indices)
Time Frame: At 0 minutes (fasting) and 4 hours after consumption of the standard breakfast meal and the SmartBar™, respectively
|
Including but not limited to Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
|
At 0 minutes (fasting) and 4 hours after consumption of the standard breakfast meal and the SmartBar™, respectively
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- H-18026293
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Participants
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
Insmed IncorporatedRecruitingHealthy ParticipantsUnited States
-
Aeovian Pharmaceuticals, Inc.RecruitingHealthy ParticipantsAustralia
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingHealthy ParticipantsChina
-
CelgeneNot yet recruitingHealthy ParticipantsUnited States
-
Bristol-Myers SquibbNot yet recruiting
-
AstraZenecaParexelRecruiting
-
ProMis Neurosciences, IncRecruiting
-
Novo Nordisk A/SRecruitingHealthy ParticipantsCanada
-
Novo Nordisk A/SRecruiting
Clinical Trials on SmartBar™
-
BaroNova, Inc.Completed
-
London Health Sciences CentreUniversity of Western Ontario, Canada; Synaptive MedicalUnknownBrain Damage, Chronic | Cerebellar Cognitive Affective Syndrome | Cerebellar Mutism
-
Asklepios Kliniken Hamburg GmbHUniversity of KielCompletedAirway Management | Laryngeal Mask Airway | Fibreoptic Intubation
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting,...RecruitingHydrocephalus | Hydrocephalus, CommunicatingArgentina
-
Medtronic CardiovascularActive, not recruitingAortic AneurysmGermany, New Zealand, United States, Netherlands, Switzerland, United Kingdom, Spain, Australia, Italy, Sweden, France, Austria, Slovakia
-
Gülçin Özalp GerçekerCompletedCatheter Complications | Catheter LeakageTurkey
-
Andrew ParrentUniversity of Western Ontario, Canada; Synaptive MedicalUnknownTemporal Lobe Epilepsy
-
Medtronic CardiovascularMedtronicCompletedAortic StenosisNew Zealand, United Kingdom, Australia
-
GlaxoSmithKlineCompletedTetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type bKorea, Republic of
-
GlaxoSmithKlineCompletedHepatitis B | Hepatitis AGermany, Belgium, Czechia